Table 4

Risk factors of OI for patients receiving anti-TNF therapy (multivariate analysis, final model)

OI cases and controls(38 cases and 114 controls)
OR (95% CI)p Value
Last anti-TNF received
 Etanercept1
 Adalimumab10.0 (2.3 to 44.4)0.002
 Infliximab17.6 (4.3 to 72.9)<0.0001
Steroids >10 mg/day or boluses during the previous year
 No1
 Yes6.3 (2.0 to 20.0)0.002
  • OI, opportunistic infection; TNF, tumour necrosis factor.